Drugs / D337
Trials 23
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 121 trials | ||||||
| Phase 1 | NCT06112678 | Jan → Feb 2024 | hyperlipidemia, hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT06088017 | Oct 2023 → Jan 2024 | hyperlipidemia | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT05698043 | Jul → Sep 2023 | hyperlipidemia, combined, 2 | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT05749861 | Apr → Jun 2023 | hyperlipidemia, combined, 2 | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT05634447 | Dec 2022 → Feb 2023 | hyperlipidemia | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT05549401 | Sep → Nov 2022 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT05552495 | Sep → Nov 2022 | hyperlipidemia, combined, 2 | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT05245084 | Mar → Jun 2022 | hyperlipidemia, combined, 2 | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT05192356 | Feb → May 2022 | hyperlipidemia, combined, 2 | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04987970 | Sep → Nov 2021 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04883658 | Jun → Jul 2021 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04694989 | Feb → Apr 2021 | hyperlipidemia, combined, 2 | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04673864 | Jan → Mar 2021 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04660370 | Jan → Feb 2021 | hyperlipidemia, combined, 2 | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04587206 | Oct → Dec 2020 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04258865 | Mar → Apr 2020 | hyperlipidemia, hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04354987 | Oct 2019 → Jan 2020 | hyperlipidemia | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT03920579 | Apr → May 2019 | hyperlipidemia, hypertensive disorder | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT03793985 | Sep → Oct 2018 | hyperlipidemia | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT03726866 | Aug 2018 → Jan 2019 | hyperlipidemia, hypertensive disorder | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT03609606 | Aug → Sep 2018 | hyperlipidemia, hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04388215 | Oct 2019 → Apr 2021 | essential hypertension, hyperlipidemia | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 3 | NCT04312698 | Aug 2019 → Jun 2021 | hyperlipidemia | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT04304547 Comparator | Feb → Apr 2020 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04223895 Background | Feb → Mar 2020 | type 2 diabetes mellitus | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT04272502 Background | Jun → Aug 2019 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D337 | “Period 1: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition” NCT05634447 ↗ |
| Route | Oral | “Daily oral administration of 1 tablet for each drug” NCT03609606 ↗ |